Applications of 4-[(4-Methylpiperazin-1-Yl)Methyl]Benzoic Acid Dihydrochloride in Industrial Manufacturing

4-[(4-Methylpiperazin-1-Yl)Methyl]Benzoic Acid Dihydrochloride supports targeted chemical synthesis as a specialty intermediate. Our direct supply and precise quality control assist downstream producers in meeting industry benchmarks for high-purity compound manufacturing. The following application fields reflect exclusively its established use in active pharmaceutical ingredient (API) syntheses, contract development for pharma intermediates, and chemical research production lines.

1. API Intermediate for Anti-Cancer Pharmaceuticals

This compound is a preferred intermediate in multi-step syntheses for certain kinase inhibitors and antitumor drugs. Downstream manufacturers incorporate it during the early heterocycle coupling stages to construct core scaffolds essential for subsequent pharmacologically active APIs. Demand for this intermediate aligns with projects involving stringent impurity profiles and consistent scale-up, requiring tight production tolerances and complete traceability across batches.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice (GMP) for Active Pharmaceutical Ingredients
• United States Pharmacopeia (USP) General Chapter <1078> Good Storage and Shipping Practices
• EU EudraLex Volume 4: GMP for APIs
• FDA 21 CFR Part 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals

Typical usage ratio

• Dosage in synthesis: 0.18 – 0.35 molar equivalents, depending on target molecular architecture; chemists adjust based on reaction yield and downstream purification requirements.

Downstream process integration

• Introduced post-initial ring construction during the amidation or alkylation phase; processed via solution-phase or solid-phase synthesis pathways; handled in closed-system reactors for strict contamination control.

Final product types

• Clinical trial-grade kinase inhibitors
• Commercial-scale oncology APIs
• Reference standards for regulated cancer drugs

2. Contract Manufacturing of Piperazine-Linked Intermediates

Chemical CDMOs select this material as a building block to expand their custom synthesis portfolios, addressing medicinal chemistry projects targeting heteroaromatic scaffolds. Its unique structure allows specific N-alkylation steps not possible with unsubstituted piperazine derivatives, supporting fast turnaround of small molecule batches with complex substitution patterns.

Industry compliance standards

• ISO 9001:2015 Quality Management Systems for Chemical Manufacturing
• REACH Regulation (EC) No 1907/2006 compliance for handling and transport
• IPEC-PQG GMP Guide for Pharmaceutical Excipients
• OECD Guideline 203: Chemical Testing Requirements

Typical usage ratio

• In custom syntheses: 5–12% weight of total batch; formulation scientists adjust based on scale, targeted molecular weight, and crude purity before chromatographic workup.

Downstream process integration

• Employed early in the synthesis—often the second or third step—directly coupled with benzyl or acyl halides; reactions typically run under inert gas and monitored by in-process HPLC for by-product tracking.

Final product types

• API intermediates for pipeline pharmaceuticals
• Synthetic reference compounds for research
• Precursor libraries for medicinal chemistry screening

3. Synthesis of CNS-Active Drug Candidates

Drug discovery groups engaged in central nervous system (CNS) research source this intermediate to build N-methylated piperazine derivatives, which serve as core components in neurotransmitter modulator compounds. The raw material supports late-stage diversification with minimal side reactions, especially in combinatorial libraries targeting serotonin or dopamine pathways.

Industry compliance standards

• FDA QSR 21 CFR Part 210/211 for investigational drug production
• Japan Pharmacopoeia compliance for CNS drug candidate work
• OECD GLP Principles for Non-Clinical Health and Environmental Safety Studies
• Schedule H regulations for handling psychoactive research molecules

Typical usage ratio

• Formulation level: 0.9–2.5% molar ratio relative to the total library pool in parallel syntheses; researchers optimize based on activity in subsequent screening assays.

Downstream process integration

• Introduced at the substitution or N-alkylation phase, frequently in microwave-assisted or flow chemistry reactors to accelerate cycle times and purity assessments in lead optimization programs.

Final product types

• Exploratory CNS drug candidates
• Research-scale neuroactive compound libraries
• Patent-protected advanced intermediates

4. Production of Diagnostic Tracer Synthesis Precursors

Specialty diagnostic reagent manufacturers utilize this chemical as a core fragment in synthesizing radiolabeled tracers and fluorescent marker compounds. Its substitution pattern enables precise attachment of imaging groups while maintaining favorable pharmacokinetic profiles during preclinical tracer evaluation.

Industry compliance standards

• United States Pharmacopeia (USP) General Chapter <823> Radiopharmaceuticals—Production, Compounding, Dispensing, and Repackaging
• GMP guidelines for PET and SPECT tracer precursor manufacturing
• ISO 13485:2016 for quality management in diagnostic device manufacturing
• FDA 21 CFR Part 212 for Current Good Manufacturing Practice for Positron Emission Tomography Drugs

Typical usage ratio

• Used in 0.04–0.12 equivalents as a key precursor in coupling and labeling stages; varies by radiolabeling efficiency and tracer structure requirements.

Downstream process integration

• Reacted during the coupling of chelating or fluorophore groups, typically in aseptic conditions to prevent contamination in injectable tracers; process includes purification by semi-preparative HPLC.

Final product types

• Positron emission tomography (PET) tracer intermediates
• Preclinical fluorescent probe precursors
• Radiolabeled diagnostic filter compounds

5. Fine Chemical Supply for Academic Research and Method Development

University laboratories and specialty chemical suppliers rely on this intermediate during new reaction method development and synthesis of mechanistic probes, thanks to its stable salt form and well-characterized reactivity. Its incorporation allows reproducible formation of designed aromatic-piperazine linkages, supporting experimental reproducibility and mechanistic studies in catalytic cycles.

Industry compliance standards

• GHS/CLP Regulation (EC) No 1272/2008 for laboratory chemical safety
• ISO/IEC 17025:2017 for general requirements in chemical testing laboratories
• Local academic procurement and safety protocols for hazardous chemicals
• REACH Annex XVII restrictions (where applicable) on specialty chemical handling

Typical usage ratio

• Experimental design: 0.1 – 0.5 mmol per run, scaled by reaction screening array; amount determined by stoichiometric need, substrate concentration, and detection limits in analytical follow-up.

Downstream process integration

• Added during optimization of C–N coupling reactions, structural probe syntheses, or catalyst turnover studies; processed under controlled atmosphere for high-yield, low-impurity outcomes.

Final product types

• Reaction intermediates for academic publication
• Method validation standards
• Mechanistic probe molecules for multi-center collaboration studies